Bristol-Myers Squibb faces new antitrust complaint over Thalomid, Revlimid
MLex Summary: Molina Healthcare filed a complaint accusing Celgene and its owner, Bristol-Myers Squibb, of illegally monopolizing the market for Thalomid and Revlimid. The complaint claims that Celgene has successfully interfered...To view the full article, register now.
Already a subscriber? Click here to view full article